Patient-based substudies from BEACH: abstracts and research tools
1999–2006

Australian GP Statistics and Classification Centre
The Australian Institute of Health and Welfare is Australia’s national health and welfare statistics and information agency. The Institute’s mission is better information and statistics for better health and wellbeing.

The Australian General Practice Statistics and Classification Centre (previously Unit) is a collaborating unit of the Australian Institute of Health and Welfare and the University of Sydney, situated within the Family Medicine Research Centre at Westmead Hospital. It fulfils the obligation of the Australian Institute of Health and Welfare to collect statistics regarding general practitioners, their patients and their patients’ care.

**Contributors**

Other members of the BEACH research team who have contributed extensively to the research reported in this document:

Janice Charles  
Salma Fahridin  
Christopher P Harrison  
Stephanie Knox

The contribution to the reported research made by past members of the BEACH team is also acknowledged:

Anthea Ng (SAND substudies 2003–2005)  
Zoe Kelly (SAND substudies 1999–2001)  
Alice Bhasale (SAND substudies 1999–2000)  
Fiona Horn (SAND substudies 1999–2000)

**Recent related publications**


Please note that as with all statistical reports there is the potential for minor revisions of data in this report over its life. Please refer to the online version at <www.aihw.gov.au>. 
BEACH
Bettering the Evaluation
And Care of Health

Patient-based substudies from BEACH: abstracts and research tools 1999–2006

Australian GP Statistics and Classification Centre

Helena Britt, Graeme C Miller, Joan Henderson, Clare Bayram

July 2007

A joint report by the University of Sydney and the Australian Institute of Health and Welfare

AIHW cat. no. GEP 20
Foreword

General practice remains the cornerstone of Australia’s health service. One has only to look at countries that do not have general practice or something similar, to see what a shambles follows. One of the troubling features about health care in the US is that primary care is often provided by specialists, at specialist rates and with concomitant use of special investigations. At the other end of socioeconomic spectrum, sub-Saharan African countries struggle to dispense medication for HIV and malaria because of a lack of primary care capacity.

Given the importance of general practice, then, it is refreshing to read the following studies that have emerged from the productive collaboration of the investigators with general practitioners in Australia. Many pharmaceutical companies, health departments and other interest groups have supported the studies. The sheer diversity of sponsorship, combined with the constancy of the research methods, diminishes the risk of biased results.

The BEACH substudies presented in this report address many aspects of health and health care of patients attending general practice. The data gathering has been appropriately parsimonious and economical of practitioners’ time, but within those constraints information is remarkably rich. Whether the point in question is asthma (study 104) or cultural background of patients attending general practice (study 95), each study summary provides clear, concise and helpful insights on which we may base strategies for assisting general practitioners the better to care for their patients or to do other things in the health service that could assist them and their patients. I defy anyone to pick up this volume and find a boring study!

The investigators who have conducted these studies deserve a sustained round of applause. Research of this sort requires strength of vision and great good will. Any research program that has run for over 10 years is truly astonishing and deserves an award for longevity. I also applaud the generosity of the sponsors and research team in making the tested research implements freely available. It is interesting to observe the growth in precision, focus and feasibility that has occurred over the two decades since their first national study in 1990–91.

I saw BEACH when it began and it has matured wonderfully. I congratulate the research workers and commend this fine report to all who have an interest in general practice in Australia.

Stephen Leeder AO, MD, PhD, BSc (Med), FRACP, FAFPHM, FFPH(UK)
Professor of Public Health and Community Medicine
Director, Australian Health Policy Institute
University of Sydney
Acknowledgments

The Australian General Practice Statistics and Classification Centre (formerly the General Practice Statistics and Classification Unit) wishes to thank the general practitioners who participated in BEACH between April 1999 and December 2006, the period covered by the abstracts in this report. Over this period there were approximately 8,500 participants, representing about 7,000 individual general practitioners. This publication would not have been possible without their valued cooperation and effort in providing the data.

We also thank the following organisations for their financial support and their contribution to the ongoing development of the BEACH program since it began in April 1998:

- Pfizer Australia (2003–2006)
- Abbott Australasia (2006)
- Sanofi-Aventis Australia Pty Ltd (2006)

Some financial support for the program was also provided by:


We acknowledge the support of the Royal Australian College of General Practitioners, the Australian Medical Association, the Australian Divisions of General Practice, the Australian College of Rural and Remote Medicine, and the Consumers Health Forum, and the contribution of their representatives to the BEACH Advisory Board.

The authors are grateful to all members of the BEACH team, both past and present, whose work has contributed to the research reported here and whose names are listed in the front of this report. We are grateful for the editing and coordination of this report by Clare Bayram and the IT support of Timothy Chambers and the administrative support of Gervaise Woods. We also recognise the general practitioner recruitment staff (particularly Errol Henderson and Jan Fitzgerald), and data entry staff.

We appreciate the cooperation of the Primary Care Division of the Australian Government Department of Health and Ageing in regularly supplying general practitioner random samples and national Medicare data.

Ethics approval for the BEACH study was obtained by the Human Ethics Committee of the University of Sydney and the Ethics Committee of the Australian Institute of Health and Welfare. Ethics approval for all the substudies reported here was obtained from the Ethics Committee of the Australian Institute of Health and Welfare, on behalf of the Institute and the University of Sydney.
# Contents

Foreword ............................................................................................................................................... v
Acknowledgments.............................................................................................................................. vi

1 Introduction................................................................................................................................... 1
  1.1 Using this publication ........................................................................................................... 3
  1.2 Interpreting the prevalence estimates ............................................................................... 4
  1.3 Background ....................................................................................................................... 5
  SAND substudies ..................................................................................................................... 5

2 Methods ......................................................................................................................................... 8
  2.1 BEACH ................................................................................................................................ 8
  2.2 SAND—Supplementary Analysis of Nominated Data ....................................................... 9
  The development of the tools for SAND substudies ............................................................ 9
  Statistical methods .................................................................................................................. 11
  Classification of data ............................................................................................................ 12

3 Lessons learnt............................................................................................................................... 13
  3.1 Rules of thumb in SAND tool design .............................................................................. 13
  3.2 Methodological issues ...................................................................................................... 19

4 SAND substudies conducted continually since April 2000 ..................................................... 20
  4.1 Body mass index of adults ............................................................................................. 20
  4.2 Body mass index of children ......................................................................................... 21
  4.3 Smoking .......................................................................................................................... 21
  4.4 Alcohol consumption ...................................................................................................... 22
  4.5 Length of consultation .................................................................................................... 23

5 Abstracts and research tools......................................................................................................... 28
  1 Allergic rhinitis.................................................................................................................... 28
  2 Anxiety/stress, consultation time, level of education ......................................................... 30
  3 Asthma ................................................................................................................................ 32
  4 Cardiovascular disease ....................................................................................................... 35
  5 Depression ........................................................................................................................... 37
  6 Employment status and workers’ compensation claims .................................................... 39
  7 Health service utilisation, lifestyle status and chronicity .................................................. 41
  8 Hormone replacement therapy (HRT) ............................................................................... 43
  9 Influenza and absenteeism ................................................................................................. 45
  10 Length of consultation; after-hours arrangements; co-morbidity ..................................... 47
  11 Patient employment status and occupation .................................................................... 50
  12 Smoking & passive smoking in general practice patients ................................................ 52
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Perceived stress</td>
<td>54</td>
</tr>
<tr>
<td>14</td>
<td>Co-medications</td>
<td>57</td>
</tr>
<tr>
<td>15</td>
<td>Lipid lowering medication</td>
<td>59</td>
</tr>
<tr>
<td>16</td>
<td>Effect of day and time of GP visit on billing method</td>
<td>61</td>
</tr>
<tr>
<td>17</td>
<td>Private prescription products</td>
<td>63</td>
</tr>
<tr>
<td>18</td>
<td>Drugs for the treatment of peptic ulcer and reflux</td>
<td>65</td>
</tr>
<tr>
<td>19</td>
<td>Osteoporosis</td>
<td>67</td>
</tr>
<tr>
<td>20</td>
<td>Screening and management of blood cholesterol</td>
<td>70</td>
</tr>
<tr>
<td>21</td>
<td>Diabetes — prevalence, management and screening</td>
<td>72</td>
</tr>
<tr>
<td>22</td>
<td>Asthma — prevalence, severity and management</td>
<td>75</td>
</tr>
<tr>
<td>23</td>
<td>Depression</td>
<td>78</td>
</tr>
<tr>
<td>24</td>
<td>Gastro-oesophageal reflux disease (GORD) in general practice patients</td>
<td>80</td>
</tr>
<tr>
<td>25</td>
<td>Prevalence of diabetes, medications and control</td>
<td>82</td>
</tr>
<tr>
<td>26</td>
<td>Prevalence of diagnosed hypertension and difficulties in treatment</td>
<td>84</td>
</tr>
<tr>
<td>27</td>
<td>Prevalence and management of influenza</td>
<td>86</td>
</tr>
<tr>
<td>28</td>
<td>Prevalence of Alzheimer’s disease and dementia</td>
<td>89</td>
</tr>
<tr>
<td>29</td>
<td>Non-steroidal anti-inflammatory drugs (NSAIDs) and acid suppressant use</td>
<td>92</td>
</tr>
<tr>
<td>30</td>
<td>Lipid lowering medications and coronary heart disease</td>
<td>94</td>
</tr>
<tr>
<td>31</td>
<td>Prevalence and severity of chronic heart failure</td>
<td>96</td>
</tr>
<tr>
<td>32</td>
<td>Patient use of after-hours medical services</td>
<td>98</td>
</tr>
<tr>
<td>33</td>
<td>Prevalence and management of cardiovascular risk factors</td>
<td>100</td>
</tr>
<tr>
<td>34</td>
<td>Gastro-oesophageal reflux disease (GORD)</td>
<td>102</td>
</tr>
<tr>
<td>35</td>
<td>Smoking status of adults and their attempts to quit</td>
<td>104</td>
</tr>
<tr>
<td>36</td>
<td>Patient use of complementary therapies</td>
<td>107</td>
</tr>
<tr>
<td>37</td>
<td>Prevalence of common morbidities in patients encountered in general practice</td>
<td>109</td>
</tr>
<tr>
<td>38</td>
<td>Prevalence of chronic heart failure, management and control</td>
<td>111</td>
</tr>
<tr>
<td>39</td>
<td>Severity of asthma, medications and management</td>
<td>113</td>
</tr>
<tr>
<td>40</td>
<td>Type 2 diabetes mellitus, prevalence and management</td>
<td>116</td>
</tr>
<tr>
<td>41</td>
<td>Time of visit and billing status</td>
<td>118</td>
</tr>
<tr>
<td>42</td>
<td>Prevalence and management of chronic pain</td>
<td>120</td>
</tr>
<tr>
<td>43</td>
<td>Initiation and purpose of pathology orders</td>
<td>122</td>
</tr>
<tr>
<td>44</td>
<td>Severity of illness</td>
<td>124</td>
</tr>
<tr>
<td>45</td>
<td>Diabetes mellitus prevalence, management and risk factors</td>
<td>126</td>
</tr>
<tr>
<td>46</td>
<td>Coronary heart disease, risk factors and lipid lowering medication</td>
<td>128</td>
</tr>
<tr>
<td>47</td>
<td>Management of depression and anxiety</td>
<td>130</td>
</tr>
<tr>
<td>48</td>
<td>Asthma prevalence and management</td>
<td>132</td>
</tr>
<tr>
<td>49</td>
<td>Health status and management of patients on non-steroidal anti-inflammatory drugs</td>
<td>135</td>
</tr>
<tr>
<td>50</td>
<td>Risk factors of patients on lipid lowering medications [interim report]</td>
<td>67</td>
</tr>
</tbody>
</table>

See Abstract 67